High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

被引:406
|
作者
Lisio, Michael-Antony [1 ]
Fu, Lili [1 ]
Goyeneche, Alicia [1 ]
Gao, Zu-hua [1 ]
Telleria, Carlos [1 ]
机构
[1] McGill Univ, Dept Pathol, Expt Pathol Unit, Montreal, PQ H3A 2B4, Canada
关键词
high-grade serous ovarian cancer; cortical inclusion cysts; serous tubular intra-epithelial carcinoma; ovarian surface epithelium; homologous recombination; BRCA; mutant p53; genetically-engineered mouse models; debulking surgery; chemotherapy; TUBAL INTRAEPITHELIAL CARCINOMA; OLAPARIB MAINTENANCE THERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; GROSS RESIDUAL DISEASE; RANDOMIZED PHASE-III; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; OPEN-LABEL; TP53; MUTATIONS; DOUBLE-BLIND;
D O I
10.3390/ijms20040952
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
引用
收藏
页数:33
相关论文
共 50 条
  • [1] Personalising Treatment for High-Grade Serous Ovarian Carcinoma
    Cojocaru, E.
    Parkinson, C. A.
    Brenton, J. D.
    CLINICAL ONCOLOGY, 2018, 30 (08) : 515 - 524
  • [2] The Changing View of High-Grade Serous Ovarian Cancer
    Berns, Els M. J. J.
    Bowtell, David D.
    CANCER RESEARCH, 2012, 72 (11) : 2701 - 2704
  • [3] Cell Origins of High-Grade Serous Ovarian Cancer
    Kim, Jaeyeon
    Park, Eun Young
    Kim, Olga
    Schilder, Jeanne M.
    Coffey, Donna M.
    Cho, Chi-Heum
    Bast, Robert C., Jr.
    CANCERS, 2018, 10 (11)
  • [4] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [5] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [6] Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
    Kurman, R. J.
    ANNALS OF ONCOLOGY, 2013, 24 : 16 - 21
  • [7] Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
    Evangelisti, Giulio
    Barra, Fabio
    Moioli, Melita
    Sala, Paolo
    Stigliani, Sara
    Gustavino, Claudio
    Costantini, Sergio
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 779 - 792
  • [8] Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
    Bowtell, David D.
    Boehm, Steffen
    Ahmed, Ahmed A.
    Aspuria, Paul-Joseph
    Bast, Robert C., Jr.
    Beral, Valerie
    Berek, Jonathan S.
    Birrer, Michael J.
    Blagden, Sarah
    Bookman, Michael A.
    Brenton, James D.
    Chiappinelli, Katherine B.
    Martins, Filipe Correia
    Coukos, George
    Drapkin, Ronny
    Edmondson, Richard
    Fotopoulou, Christina
    Gabra, Hani
    Galon, Jerome
    Gourley, Charlie
    Heong, Valerie
    Huntsman, David G.
    Iwanicki, Marcin
    Karlan, Beth Y.
    Kaye, Allyson
    Lengyel, Ernst
    Levine, Douglas A.
    Lu, Karen H.
    McNeish, Iain A.
    Menon, Usha
    Narod, Steven A.
    Nelson, Brad H.
    Nephew, Kenneth P.
    Pharoah, Paul
    Powell, Daniel J., Jr.
    Ramos, Pilar
    Romero, Iris L.
    Scott, Clare L.
    Sood, Anil K.
    Stronach, Euan A.
    Balkwill, Frances R.
    NATURE REVIEWS CANCER, 2015, 15 (11) : 668 - 679
  • [9] Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
    Kandalaft, Lana E.
    Laniti, Denarda Dangaj
    Coukos, George
    NATURE REVIEWS CANCER, 2022, 22 (11) : 640 - 656
  • [10] Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
    Gadducci, Angiolo
    Guarneri, Valentina
    Peccatori, Fedro Alessandro
    Ronzino, Graziana
    Scandurra, Giuseppa
    Zamagni, Claudio
    Zola, Paolo
    Salutari, Vanda
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)